D-0233-2025 Class II Ongoing
FDA drug recall D-0233-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Jan 29, 2025 and is designated Class II. Reason for recall: CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit. The recall status is ongoing. Affected quantity: 175,920 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 26, 2025
- Initiation Date
- Jan 29, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 175,920 bottles
Product description
Atomoxetine Capsules, USP, 25 mg, 30 capsule bottles, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ, USA, Product of India, NDC 68462-267-30.
Reason for recall
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Distribution pattern
Nationwide within the U.S
Code information
Lot Numbers: 19233792, Exp.: 8/2025; 19233795, Exp.: 8/2025; 19234258, Exp.: 9/2025; 19240912, Exp.: 2/2026; 19241476, 19241477, Exp.: 3/2026; 19242599, Exp.: 6/2026; 19243163, 19243162, Exp.:7/2026;19243884, 19243887, Exp.:9/2026.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0233-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026